Chardan Capital Maintains Buy on Arbutus Biopharma, Maintains $5 Price Target
Benzinga Newsdesk 11 months ago
NewsPrice TargetAnalyst Ratings
Chardan Capital analyst Keay Nakae maintains Arbutus Biopharma (NASDAQ:ABUS) with a Buy and maintains $5 price target.
Chardan Capital analyst Keay Nakae maintains Arbutus Biopharma (NASDAQ:ABUS) with a Buy and maintains $5 price target.